A rationally grounded approach to treating gout with regard to its onset and course and the presence of comorbidity according to the European League against Rheumatism (EULAR 2016) recommendations


Cite item

Full Text

Abstract

The review analyzes in detail the management of gout, which takes into account its onset and course and the presence of comorbidity. Emphasis is placed on drug and non-drug treatments and urate-lowering therapy in patients with kidney dysfunction. Along with allopurinol, the urate-lowering drug febuxostat is first recommended in Russia. The purpose of this review is to notify physicians of the possibility of achieving the target uric acid levels when treating gout with hyperuricemia.

About the authors

V V Tsurko

ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России; ФГБОУ ВО «РНИМУ им. Н.И. Пирогова» Минздрава России

Москва, Россия

M A Gromova

ФГБОУ ВО «РНИМУ им. Н.И. Пирогова» Минздрава России

Москва, Россия

References

  1. Hootman JM, Helmick CG. Projections of US prevalence of arthritis and associated activity limitations. Arthritis Rheum. 2006;54(1):226-229.
  2. Насонова В.А., Барскова В.Г. Ранние диагностика и лечение подагры — научно обоснованное требование улучшения трудового и жизненного прогноза больных. Научно-практическая ревматология. 2004;1:5-7.
  3. Luk AJ, Simkin PA. Epidemiology of hyperuricemia and gout. Am J Manag Care. 2005;11(15,Suppl):S435-442.
  4. Choi JW, Ford ES, Gao X., Choi HK. Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2008;59(1):109-116.
  5. Geiderman JM. An elderly woman with a warm, painful finger. West J Med. 2000;172(1):51-52.
  6. Атаханова Л.Э., Цурко В.В., Булеева И.М. Бойко И.Н., Железнов С.П., Иванова Т.Б. Подагра: от этиологии и патогенеза к диагностике и рациональной терапии. Современная ревматология. 2007;1:13-18.
  7. Simkin PA, Campbell PM, Larson EB. Gout in Heberden’s nodes. Arthritis Rheum. 1983;26(1):94-107.
  8. Воробьев П.А., Цурко В.В., Елисеева М.Е. Подагра в гериатрической практике (методические рекомендации. Часть I). Клиническая геронтология. 2016;3-4(22):3-9.
  9. Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M. Eligibility for and prescription of urate-lowering treatment in patients with incident gout in England. JAMA. 2014;312(24):2684-2686. https://doi.org/10.1001/jama.2014.14484
  10. Rees F., Jenkins W., Doherty M. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann Rheum Dis. 2013;72(6):826-830. https://doi.org/10.1136/annrheumdis-2012-201676
  11. Dalbeth N, Chen P, White M, Gamble GD, Barratt-Boyes C, Gow PJ, Orr-Walker B. Impact of bariatric surgery on serum urate targets in people with morbid obesity and diabetes: a prospective longitudinal study. Ann Rheum Dis. 2014;73(5):797-802. https://doi.org/10.1136/annrheumdis-2013-203970
  12. Цурко В.В., Елисеева М.Е., Воробьев П.А. Особенности течения подагры в пожилом возрасте. Терапевтический архив. 2014;5(86):50-55.
  13. Chen JH, Wen CP, Wu SB, Lan JL, Tsai MK, Tai YP, Lee JH, Hsu CC, Tsao CK, Wai JP, Chiang PH, Pan WH, Hsiung CA. Attenuating the mortality risk of high serum uric acid: the role of physical activity underused. Ann Rheum Dis. 2015;74(11):2034-2042. https://doi.org/10.1136/annrheumdis-2014-205312
  14. Roddy E, Choi HK. Epidemiology of gout. Rheum Dis Clin North Am. 2014;40(2):155-175. https://doi.org/10.1016/j.rdc.2014.01.001
  15. Zhang Y, Neogi T, Chen C, Chaisson C, Hunter DJ, Choi HK. Cherry consumption and decreased risk of recurrent gout attacks. Arthritis Rheum. 2012;64:4004-4011. https://doi.org/10.1002/art.34677
  16. Dalbeth N, Ames R, Gamble GD, Horne A, Wong S, Kuhn-Sherlock B, MacGibbon A, McQueen FM, Reid IR, Palmano K. Effects of skim milk powder enriched with glycomacropeptide and G600 milk fat extract on frequency of gout flares: a proof-of-concept randomised controlled trial. Ann Rheum Dis. 2012;71(6):929-934. https://doi.org/10.1136/annrheumdis-2011-200156
  17. Liu SC, Xia L, Zhang J, Lu XH, Hu DK, Zhang HT, Li HJ. Gout and risk of myocardial infarction: a systematic review and meta-analysis of cohort studies. PLoS One. 2015;10(7):e0134088. https://doi.org/10.1371/journal.pone.0134088
  18. Clarson LE, Hider SL, Belcher J, Heneghan C, Roddy E, Mallen CD. Increased risk of vascular disease associated with gout: a retrospective, matched cohort study in the UK clinical practice research datalink. Ann Rheum Dis. 2015;74(4):642-647. https://doi.org/10.1136/annrheumdis-2014-205252
  19. Choi H.K., Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation. 2007;116(8):894-900.
  20. Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010;62:1060-1068. https://doi.org/10.1002/art.27327
  21. van Durme CM, Wechalekar MD, Buchbinder R, Schlesinger N, van der Heijde D, Landewé RB. Non-steroidal anti-inflammatory drugs for acute gout. Cochrane Database Syst Rev. 2014;(9): CD010120. https://doi.org/10.1002/14651858
  22. Rainer TH, Cheng CH, Janssens HJ, Man CY, Tam LS, Choi YF, Yau WH, Lee KH, Graham CA. Oral prednisolone in the treatment of acute gout: a pragmatic, multicenter, double-blind, randomized trial. Ann Intern Med. 2016;164(7):464-4671. https://doi.org/10.7326/M14-2070
  23. Terkeltaub RA, Furst DE, Digiacinto JL, Kook KA, Davis MW. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis Rheum. 2011;63:2226-2237. https://doi.org/10.1002/art.30389
  24. Wason S., Mount D., Faulkner R. Single-dose, open-label study of the differences in pharmacokinetics of colchicine in subjects with renal impairment, including end-stage renal disease. Clin Drug Investig. 2014;34(12):845-855. https://doi.org/10.1007/s40261-014-0238-6
  25. Janssens HJ, Janssen M, van de Lisdonk EH, van Riel PL, van Weel C. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomized equivalence trial. Lancet. 2008;371(9627):1854-1860. https://doi.org/10.1016/S0140-6736(08)60799-0
  26. Wechalekar MD, Vinik O, Schlesinger N, Buchbinder R. Intra-articular glucocorticoids for acute gout. Cochrane Database Syst Rev. 2013;(4): CD009920. https://doi.org/10.1002/14651858.CD009920
  27. Schlesinger N, Alten RE, Bardin T, Schumacher HR, Bloch M, Gimona A, Krammer G, Murphy V, Richard D, So AK. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis. 2012;71(11):1839-1848. https://doi.org/10.1136/annrheumdis-2011-200908
  28. Ghosh P, Cho M, Rawat G, Simkin PA, Gardner GC. Treatment of acute gouty arthritis in complex hospitalized patients with anakinra. Arthritis Care Res (Hoboken). 2013;65(8):1381-1384. https://doi.org/10.1002/acr.21989
  29. Becker MA, MacDonald PA, Hunt BJ, Lademacher C, Joseph-Ridge N. Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. Nucleosides Nucleotides Nucleic Acids. 2008;27(6):585-591. https://doi.org/10.1080/15257770802136032
  30. Wortmann RL, Macdonald PA, Hunt B, Jackson RL. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. ClinTher. 2010;32(14):2386-2397. https://doi.org/10.1016/j.clinthera.2011.01.008
  31. Finkelstein Y, Aks SE, Hutson JR, Juurlink DN, Nguyen P, Dubnov-Raz G, Pollak U, Koren G, Bentur Y. Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol (Phila). 2010;48(5):407-414. https://doi.org/10.3109/15563650.2010.495348
  32. Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, Lademacher C, Joseph-Ridge N. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008;59(11):1540-1548. https://doi.org/10.1002/art.24209
  33. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450-2461.
  34. Clarson LE, Hider SL, Belcher J, Heneghan C, Roddy E, Mallen CD. Increased risk of vascular disease associated with gout: a retrospective, matched cohort study in the UK clinical practice research datalink. Ann Rheum Dis. 2015;74(4):642-647. https://doi.org/10.1136/annrheumdis-2014-205252
  35. Noman A, Ang DS, Ogston S, Lang CC, Struthers AD. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet. 2010;375(9732):2161-2167. https://doi.org/10.1016/S0140-6736(10)60391-1
  36. Givertz MM, Anstrom KJ, Redfield MM, Deswal A, Haddad H, Butler J, Tang WH, Dunlap ME, LeWinter MM, Mann DL, Felker GM, O’Connor CM, Goldsmith SR, Ofili EO, Saltzberg MT, Margulies KB, Cappola TP, Konstam MA, Semigran MJ, McNulty SE, Lee KL, Shah MR, Hernandez AF. Effects of xanthine oxidase inhibition in hyperuricemic heart failure patients: the xanthine oxidase inhibition for hyperuricemic heart failure patients (EXACT-HF) study. Circulation. 2015;131(20):1763-1771. https://doi.org/10.1016/S0140-6736(10)60391-1
  37. Rothenbacher D, Primatesta P, Ferreira A, Cea-Soriano L, Rodríguez LA. Frequency and risk factors of gout flares in a large population-based cohort of incident gout. Rheumatology (Oxford). 2011;50(5):973-981. https://doi.org/10.1093/rheumatology/keq363
  38. Yamanaka H. Gout and hyperuricemia in young people. Curr Opin Rheumatol. 2011;23(2): 156-60. https://doi.org/10.1097/BOR.0b013e3283432d35
  39. Bardin T. Hyperuricemia starts at 360 micromoles (6 mg/dL). Joint Bone Spine. 2015;82(3):141-143. https://doi.org/10.1016/j.jbspin.2015.01.002
  40. Weisskopf MG, O’Reilly E, Chen H, Schwarzschild MA, Ascherio A. Plasma urate and risk of Parkinson’s disease. Am J Epidemiol. 2007; 166(5): 561-567.
  41. Kim TS, Pae CU, Yoon SJ, Jang WY, Lee NJ, Kim JJ, Lee SJ, Lee C, Paik IH, Lee CU. Decreased plasma antioxidants in patients with Alzheimer’s disease. Int J Geriatric Psychiatry. 2006;21(4):344-348.
  42. Abraham A., Drory V.E. Influence of serum uric acid levels on prognosis and survival in amyotrophic lateral sclerosis: a meta-analysis. J Neurol. 2014; 261(6):1133-1138. https://doi.org/10.1007/s00415-014-7331-x
  43. Rees F., Jenkins W., Doherty M. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann Rheum Dis. 2013;72(6):826-830. https://doi.org/10.1136/annrheumdis-2012-201676
  44. Halevy S, Ghislain PD, Mockenhaupt M, Fagot JP, Bouwes Bavinck JN, Sidoroff A, Naldi L, Dunant A, Viboud C, Roujeau JC. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol. 2008;58(1):25-32.
  45. Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, Lademacher C, Joseph-Ridge N. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008;59(11):1540-1548. https://doi.org/10.1002/art.24209
  46. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450-2461.
  47. Becker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E, Lademacher C. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. ArthritisResTher. 2010;12(2):R63. https://doi.org/10.1186/ar2978
  48. Hira D, Chisaki Y, Noda S, Araki H, Uzu T, Maegawa H, Yano Y, Morita SY, Terada T. Population pharmacokinetics and therapeutic efficacy of febuxostat in patients with severe renal impairment. Pharmacology. 2015;96(1-2):90-98. https://doi.org/10.1159/000434633
  49. Abeles AM. Febuxostat hypersensitivity. J Rheumatol. 2012;39(3): 659. https://doi.org/10.3899/jrheum.111161
  50. Chohan S. Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions. J Rheumatol. 2011;38(9):1957-1959. https://doi.org/10.3899/jrheum.110092
  51. Bardin T, Chalès G, Pascart T, Flipo RM, Korng Ea H, Roujeau JC, Delayen A, Clerson P. Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment. Joint Bone Spine. 2016;83(3):314-317. https://doi.org/10.1016/j.jbspin.2015.07.011
  52. Kydd AS, Seth R, Buchbinder R, Edwards CJ, Bombardier C. Uricosuric medications for chronic gout. Cochrane Database Syst Rev. 2014;(11): CD010457. https://doi.org/10.1002/14651858.CD010457
  53. Choi HK, Soriano LC, Zhang Y, Rodríguez LA. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ. 2012;344:d8190. https://doi.org/10.1136/bmj.d8190
  54. Derosa G, Maffioli P, Sahebkar A. Plasma uric acid concentrations arereduced by fenofibrate: a systematic review and meta-analysis of randomized placebocontrolled trials. Pharmacol Res. 2015;102:63-70. https://doi.org/10.1016/j.phrs.2015.09.012
  55. Takagi H, Umemoto T. Atorvastatin therapy reduces serum uric acid levels: a meta-analysis of randomized controlled trials. Int J Cardiol. 2012;157(2):255-257. https://doi.org/10.1016/j.ijcard.2012.01.092

Copyright (c) 2017 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies